Genmab A/S Financial Ratios
NASDAQ: GMABHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Genmab A/S ratio analysis
Genmab A/S earned a net margin of 25.9% in FY 2025, down from 36.3% a year earlier. Gross margin was 93.6% compared with a median of 97.0% over the prior 2 years. Return on equity reached 16.5%, meaning Genmab A/S generated 0.16 dollars of profit for every dollar of shareholders' equity.
Debt-to-equity stood at 0.90 versus 0.00 the year before, and the current ratio was 2.02. At the end of FY 2025, GMAB traded at 2.1 times earnings; across the 3 fiscal years shown, its year-end P/E ranged from 1.2 to 3.3, with a median of 2.1. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Genmab A/S financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| P/E ratio (at fiscal year end) | 2.07 | 1.22 | 3.32 |
| Price / sales | 0.55 | 0.45 | 0.88 |
| Price / book | 0.35 | 0.28 | 0.45 |
| Gross margin | 93.6% | 95.4% | 98.6% |
| Operating margin | 28.6% | 31.1% | 32.3% |
| Net margin | 25.9% | 36.3% | 26.4% |
| Free cash flow margin | 30.9% | 35.2% | 42.6% |
| Return on equity (ROE) | 16.5% | 22.1% | 13.5% |
| Return on assets (ROA) | 7.5% | 17.7% | 12.1% |
| Debt / equity | 0.90 | 0.00 | 0.00 |
| Current ratio | 2.02 | 5.24 | 13.35 |
| Revenue growth | 19.2% | 30.6% | — |
| EPS growth | -12.3% | 83.0% | — |